iPSC-Based Clinical Trial Selection for Ultrarare Diseases
2026-04-20
This study introduces a patient-specific iPSC platform to prescreen drug efficacy and safety for individuals with ultrarare genetic diseases, directly addressing the uncertainty in conventional clinical trial enrollment. The approach demonstrates how personalized cellular models can refine treatment selection and advance precision medicine for rare metabolic disorders.
Cl-Amidine trifluoroacetate salt: Precision PAD4 Inhibition
2026-04-19
Cl-Amidine (trifluoroacetate salt) stands out as a selective PAD4 inhibitor, enabling researchers to dissect histone citrullination and immune regulation in cancer, autoimmunity, and septic shock models. Its robust performance in both in vitro and in vivo assays offers workflow advantages, especially where mechanistic specificity and reproducibility are paramount.
Prostaglandin E2: Optimizing Inflammation Research Workflows
2026-04-18
Prostaglandin E2 (PGE2) powers advanced inflammation research, immune regulation, and gastrointestinal protection studies with high receptor selectivity and reproducibility. This article delivers actionable protocol guidance and troubleshooting strategies to maximize data quality using APExBIO’s highly pure PGE2.
In Vivo Pharmacokinetics of RG108: Insights for DNMT Inhibit
2026-04-17
This study systematically examines the pharmacokinetics of RG108, a non-nucleosidic DNA methyltransferase inhibitor, after subcutaneous administration in rats. The findings highlight RG108’s favorable tissue distribution, safety profile, and suitability for in vivo epigenetic modulation, with implications for research beyond oncology.
3X (DYKDDDDK) Peptide: Raising the Bar for Translational Pro
2026-04-16
Explore how the 3X (DYKDDDDK) Peptide empowers translational researchers with advanced mechanistic insight and strategic guidance. This article uniquely integrates recent structural biology findings, including SPFH complexes, to demonstrate how the 3X FLAG peptide unlocks new dimensions in affinity purification, immunodetection, and protein crystallization. Discover how APExBIO’s offering sets a new standard for reproducibility, sensitivity, and workflow adaptability—bridging the gap between biological discovery and clinical innovation.
POx-Lipid Nanoparticles: A PEG-Free Platform for mRNA Delive
2026-04-15
This study introduces poly(2-ethyl-2-oxazoline) (POx) lipids as alternatives to PEG-lipids in lipid nanoparticle (LNP) formulations for mRNA delivery. The work demonstrates that POx-lipids enable efficient mRNA encapsulation, mitigate immune reactivity associated with PEG, and maintain or enhance transfection efficiency, providing valuable insight for next-generation gene delivery systems.
THBS1 as a Prognostic and Therapeutic Target in Laryngeal Ca
2026-04-14
This study applies integrative bioinformatics and in vitro validation to identify THBS1 as both a prognostic biomarker and a potential therapeutic vulnerability in laryngeal cancer. The findings highlight altered lipid metabolism among key pathways in tumor progression and provide analytic and experimental evidence for THBS1’s role in shaping the tumor microenvironment and patient outcomes.
RWJ 67657: Precision p38 MAPK Inhibition in Cytokine Researc
2026-04-13
RWJ 67657 (JNJ-3026582) elevates inflammatory disease research by combining potent, isoform-selective p38 MAP kinase blockade with an innovative mechanism that enhances dephosphorylation of p38α. This dual-action profile enables researchers to dissect cytokine regulation with unprecedented specificity and reliability.
Kaixin Jieyu Granule Modulates PI3K/Akt Pathway in Depressio
2026-04-12
Xu et al. (2023) systematically demonstrate that Kaixin Jieyu Granule (KJG) alleviates neuroinflammation-induced depressive-like behaviors in mice by targeting the TLR4/PI3K/AKT/FOXO1 signaling axis. Their combined network pharmacology and experimental approach clarifies the molecular mechanisms of KJG, providing a robust framework for future therapeutic research on depression and neuroinflammation.
Homoharringtonine as a Potent SARS-CoV-2 Inhibitor: Evidence
2026-04-12
A recent study demonstrates that homoharringtonine, a cytotoxic alkaloid and known protein synthesis inhibitor, rapidly clears SARS-CoV-2 from the upper respiratory tract in both animal models and humans. This finding positions homoharringtonine as a promising candidate for first-line defense in future coronavirus outbreaks, with broad implications for antiviral research.
Fulvestrant (ICI 182,780): Advanced Applied Workflows in ER+
2026-04-11
Fulvestrant (ICI 182,780) enables precise estrogen receptor antagonism and MDM2 protein degradation, elevating apoptosis induction and chemosensitization in ER-positive breast cancer assays. Discover protocol refinements, troubleshooting strategies, and actionable insights that leverage APExBIO’s trusted formulation for research excellence.
Omeprazole (A2845): Protocol Guidance for H+,K+-ATPase Inhib
2026-04-11
Omeprazole (SKU A2845) is a well-characterized H+,K+-ATPase inhibitor designed for research on gastric acid secretion and antiulcer mechanisms. This compound is best suited for in vitro and in vivo studies modeling gastric acid-related disorders where precision in acid inhibition is critical. It should not be repurposed for diagnostic or clinical applications.
(S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methy...
2026-04-10
(S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea (BPN-19186) is a research-grade, high-purity fluorinated phenyl urea compound from APExBIO, used for biochemical pathway analysis and enzyme inhibition studies. Its robust solubility in DMSO/ethanol and mechanism targeting the Nrf2 pathway make it a valuable tool for signal transduction and bone metabolism research.
Filipin III: Gold-Standard Cholesterol Detection for Memb...
2026-04-09
Filipin III, a polyene macrolide antibiotic, is the gold-standard cholesterol-binding fluorescent probe for membrane biochemistry research. Its unparalleled specificity for cholesterol, high-contrast visualization via freeze-fracture electron microscopy, and robust evidence base make it essential for mapping membrane cholesterol microdomains and metabolic reprogramming.
nor-Binaltorphimine Dihydrochloride in Opioid Receptor Ci...
2026-04-08
Explore the scientific impact of nor-Binaltorphimine dihydrochloride, a leading κ-opioid receptor antagonist, in decoding opioid receptor signaling and pain modulation. This article delves into advanced mechanistic insights and emerging circuit-level applications, offering a unique perspective for neuroscience and pharmacology researchers.
466 records 22/32 page Previous Next First page 上5页 2122232425 下5页 Last page